EGFR and colorectal carcinoma: In the treatment of CRC and/or PDAC patients, 3 types of polytherapy are being tested: RMC-6236 with 5-fluorouracil-based regimens; RMC-6236 and cetuximab (anti-EGFR) with or w/o mFOLFOX6, RMC-6236 combined with both gemcitabine and nab-paclitaxel (NCT06445062).